Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514444 · ClinicalTrials.gov registry record · Phase 1
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
A Phase 1 study of Neoplasms and Advanced/Metastatic Solid Tumors, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT05514444 is a Phase 1 study of Neoplasms and Advanced/Metastatic Solid Tumors that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 64 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT05514444, a Phase 1 study of Neoplasms and Advanced/Metastatic Solid Tumors, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL MK-4464
- DRUG 89Zr-MK-4464
Study Locations (6)
Other
- Rambam Health Care Campus-Oncology Division ( Site 0300) - Haifa
- Hadassah Medical Center-Oncology ( Site 0302) - Jerusalem
North Holland
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0401) - Amsterdam
- Amsterdam UMC, locatie VUmc ( Site 0400) - Amsterdam
Kentucky
- The University of Louisville, James Graham Brown Cancer Center ( Site 0100) - Louisville
Ontario
- Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201) - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-09-25 |
| Est. Completion | 2025-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05514444
The ClinicalTrials.gov registry entry for NCT05514444 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05514444 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Other, North Holland, Kentucky.
Frequently Asked Questions
What is clinical trial NCT05514444 about?
NCT05514444 is a clinical study titled "Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)". The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.
What is the current status of trial NCT05514444?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2022-09-25. Estimated completion is 2025-09-18.
What conditions does trial NCT05514444 study?
This clinical trial studies the following conditions: Neoplasms, Advanced/Metastatic Solid Tumors.
What interventions are being tested in trial NCT05514444?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-4464 (BIOLOGICAL), 89Zr-MK-4464 (DRUG).
Who is sponsoring clinical trial NCT05514444?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05514444 being conducted?
This trial has 6 study locations across Kentucky, Ontario, North Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.